Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for adjuvant treatment of renal cell carcinoma after nephrectomy.
Status In progress
Process STA 2018
ID number 3810

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
16 November 2020 - 14 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
02 August 2019 In progress. DHSC referral received 02/08/2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance